# Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

> **NCT04827056** · PHASE1 · COMPLETED · sponsor: **Pharmacotherapies for Alcohol and Substance Use Disorders Alliance** · enrollment: 10 (actual)

## Conditions studied

- Alcohol Use Disorder (AUD)
- Post Traumatic Stress Disorder (PTSD)

## Interventions

- **DRUG:** Placebo
- **DRUG:** Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
- **DRUG:** Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
- **PROCEDURE:** Ethanol Infusion
- **BEHAVIORAL:** PTSD Reactivity Condition
- **BEHAVIORAL:** Alcohol Cue Reactivity

## Key facts

- **NCT ID:** NCT04827056
- **Lead sponsor:** Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-09
- **Primary completion:** 2023-05-02
- **Final completion:** 2023-06-02
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-10-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04827056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04827056, "Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04827056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*